PEJM.F Stock Overview
Engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Peijia Medical Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.39 |
52 Week High | HK$1.39 |
52 Week Low | HK$1.39 |
Beta | 0.24 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
PEJM.F | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | 1.5% | 2.2% |
1Y | n/a | 20.8% | 31.6% |
Return vs Industry: Insufficient data to determine how PEJM.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how PEJM.F performed against the US Market.
Price Volatility
PEJM.F volatility | |
---|---|
PEJM.F Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 8.1% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PEJM.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PEJM.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 927 | Yi Zhang | www.peijiamedical.com |
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply.
Peijia Medical Limited Fundamentals Summary
PEJM.F fundamental statistics | |
---|---|
Market cap | US$887.76m |
Earnings (TTM) | -US$59.21m |
Revenue (TTM) | US$36.42m |
24.5x
P/S Ratio-15.1x
P/E RatioIs PEJM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PEJM.F income statement (TTM) | |
---|---|
Revenue | CN¥250.83m |
Cost of Revenue | CN¥74.63m |
Gross Profit | CN¥176.20m |
Other Expenses | CN¥584.01m |
Earnings | -CN¥407.81m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.61 |
Gross Margin | 70.25% |
Net Profit Margin | -162.58% |
Debt/Equity Ratio | 4.8% |
How did PEJM.F perform over the long term?
See historical performance and comparison